Arch Therapeutics (ARTH)
(Delayed Data from OTC)
$0.77 USD
0.00 (0.00%)
Updated Jul 23, 2024 01:25 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Arch Therapeutics, Inc. [ARTH]
Reports for Purchase
Showing records 41 - 60 ( 115 total )
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
Answering Questions About the 510(k) Application Process for Arch?s AC5 Topical Gel.
Provider: IFS Securities, Inc.
Analyst: BOUCHEY D
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
Skin Sensitization Study Results Provide No Surprises; Clear Path to Regulatory Review; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
Highlights of Arch Therapeutics Presentation at Investor Conference
Provider: IFS Securities, Inc.
Analyst: BOUCHEY D
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
AC5 Topical Clears Sensitization Hurdle, 510k Filing Expected September
Provider: Roth Capital Partners, Inc.
Analyst: SOLOMON D
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
Poster Presentation at Department of Defense Meeting; F3Q18 Financials Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
Preview of AC5''s Pipeline as Sensitization Data Looms
Provider: Roth Capital Partners, Inc.
Analyst: SOLOMON D
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
Reports Financial Results of its June Quarter In-Line with Expectations
Provider: IFS Securities, Inc.
Analyst: BOUCHEY D
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
F3Q18 Recap - Sensitization Data by Sept; PT to $1.55
Provider: Roth Capital Partners, Inc.
Analyst: SOLOMON D
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.